See the US opportunity before you commit.
Independent market overviews, gross-to-net projections and forecasts for your portfolio, from products already approved to molecules you are still evaluating.
A clear, realistic view of the market.
Built from experience in the US generic and injectable market, not just published data.
Full market overview
Market size, competitors, pricing trends and customer channels for each product.
Gross-to-net projection
What a product is realistically expected to earn after the deductions of the US market.
Volume and revenue forecasts
Multi-year projections of volume, price and market share.
Scenario analysis
How the outlook changes as competitors enter or market conditions shift.
From today’s products to tomorrow’s filings.
We analyze products at every stage, so you can plan the portfolio as a whole.
Approved products
Where each product stands today and what it should be earning.
Products awaiting approval
What to expect at launch and in the years that follow.
Development and filing
Which molecules are worth developing and filing for the US market.
Better decisions, backed by numbers.
- Comparing offers from potential US partners.
- Setting realistic expectations before signing.
- Checking an existing partnership against the market.
- Deciding which molecules to develop and file.
- Supporting board and investor discussions.
- Planning capacity and supply for the US.